Loading
Skye Bioscience, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by 5AM Partners VII, LLC, was filed 15 Mar 2024.
Skye Bioscience, Inc.: what insiders have been doing
Every trade that managers of Skye Bioscience, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 23 October 2026, brought 16 filings signed by 2 insiders.
There is no open-market purchase to report; the filings show 15 sales worth €386k by 1 insider. Biggest ticket of the year: €162k, sold by 5AM Partners VII, LLC and made public on 24 September 2026 (2.6% of market cap).
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (3,167 companies, median 24 filings), a count of 16 filings is below the norm. Since 2017, the database holds 6 purchases and 34 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -55.9 m USD.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
107
Thresholds
n/a
Buy Volume
€15M
6 ops. · all time
Sell Volume
€4M
34 ops. · all time
Who traded when
BuySale5AM Partners VII, LLC18 sales
Kaitlyn Arsenault3 sales
Paul A. Grayson2 sales
Punit Dhillon2 sales
Tuan Tu Diep2 sales
Andrew J. Schwab1 sale
Since the insiders bought
- -81.3%Entry US$108.00 · Close at T+365 US$20.24
- +59.7%Entry US$32.00 · Close at T+365 US$51.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.62
Analyst consensus
4 analysts2.00/5
US$16.00Target US$68.00(+4098%)US$160.00
Income statement
EBITDA-US$55.2M
Net income-US$55.9M0.0% margin
Valuation
PER (forward)-0.2x
P/Book0.5x
Beta2.86
Balance sheet & cash
Market capUS$7.2M
Total debtUS$273.6k
Free Cash Flow-US$43.1M
Debt / Equity3%
Profitability & ownership
ROE-233.9%
ROA-95.1%
% insiders4.2%
% institutions46.1%
Last declaration on 24 September 2026
Declarations107 total
27,612 shares@ US$1.650.63% mcap0.2% of flowCommon StockSEC:0001231919-26-001224:0
1,088 shares@ US$1.650.025% mcap0.0% of flowCommon StockSEC:0001231919-26-001224:1
114,851 shares@ US$1.612.58% mcap1.0% of flowCommon StockSEC:0001231919-26-001224:2
4,528 shares@ US$1.610.10% mcap0.0% of flowCommon StockSEC:0001231919-26-001224:3
27,612 shares@ US$1.650.61% mcap0.2% of flowCommon StockSEC:0001598549-26-000015:0
1,088 shares@ US$1.650.024% mcap0.0% of flowCommon StockSEC:0001598549-26-000015:1
114,851 shares@ US$1.612.49% mcap0.9% of flowCommon StockSEC:0001598549-26-000015:2
4,528 shares@ US$1.610.098% mcap0.0% of flowCommon StockSEC:0001598549-26-000015:3
32,607 shares@ US$1.910.88% mcap0.3% of flowCommon StockSEC:0001231919-26-001197:0
1,285 shares@ US$1.910.035% mcap0.0% of flowCommon StockSEC:0001231919-26-001197:1
32,607 shares@ US$1.910.83% mcap0.3% of flowCommon StockSEC:0001598549-26-000013:0
1,285 shares@ US$1.910.033% mcap0.0% of flowCommon StockSEC:0001598549-26-000013:1
1,159 shares@ US$0.320.0049% mcap0.0% of flowCommon StockSEC:0001231919-26-000959:6
6,495 shares@ US$0.320.027% mcap0.0% of flowCommon StockSEC:0001231919-26-000959:8
45,090 shares@ US$0.380.23% mcap0.1% of flowCommon StockSEC:0001231919-26-000959:0
1,830 shares@ US$0.380.0092% mcap0.0% of flowCommon StockSEC:0001231919-26-000959:1
253,080 shares@ US$0.381.28% mcap0.5% of flowCommon StockSEC:0001231919-26-000959:2
10,255 shares@ US$0.350.048% mcap0.0% of flowCommon StockSEC:0001231919-26-000959:3
409 shares@ US$0.350.0019% mcap0.0% of flowCommon StockSEC:0001231919-26-000959:4
57,476 shares@ US$0.350.27% mcap0.1% of flowCommon StockSEC:0001231919-26-000959:5
46 shares@ US$0.320.0002% mcap0.0% of flowCommon StockSEC:0001231919-26-000959:7
409 shares@ US$0.350.0019% mcap0.0% of flowCommon StockSEC:0001598549-26-000005:4
6,495 shares@ US$0.320.027% mcap0.0% of flowCommon StockSEC:0001598549-26-000005:8
45,090 shares@ US$0.380.23% mcap0.1% of flowCommon StockSEC:0001598549-26-000005:0
1,830 shares@ US$0.380.0092% mcap0.0% of flowCommon StockSEC:0001598549-26-000005:1
25 of 107 declarations
About Skye Bioscience, Inc.
Skye Bioscience, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker SKYE. The company is headquartered in San Diego, California, and was incorporated in Nevada on March 16, 2011. Today, Skye is positioned as a clinical-stage biotech focused on next-generation molecules that modulate G-protein-coupled receptors (GPCRs) to address obesity, overweight, and related metabolic conditions. For French-speaking investors in France, Belgium, and Switzerland, this places Skye in the high-risk, high-upside segment of small-cap biotech: it has no commercial revenue yet, but it is pursuing a differentiated scientific strategy in a very large therapeutic market.
Skye’s strategic evolution is notable. The company previously communicated broader ambitions around cannabinoid-system biology, but its more recent messaging has shifted toward metabolic health and GPCR-based drug development. Its lead development asset is nimacimab, a clinical-stage candidate intended to explore new pathways in obesity and metabolic regulation. As a result, Skye remains firmly in the R&D phase: it is devoting substantially all of its efforts to pipeline advancement, preclinical and clinical work, manufacturing readiness, and capital raising. That is typical for a biotech at this stage, but it also means the company is highly dependent on external financing and on clinical execution.
Read moreShow less
From a competitive standpoint, Skye operates in one of the most crowded areas of healthcare investing: obesity therapeutics. Large pharmaceutical companies and specialized biotech peers are all competing for share in a market driven by strong medical need and major commercial interest. Skye’s potential advantage lies in its scientific platform and in its focus on GPCR modulation, which may offer a distinct mechanism relative to more established treatment approaches. However, at this stage it remains a niche, pre-commercial player whose equity story depends largely on clinical data readouts, safety, efficacy signals, and future financing conditions.
Geographically, the business is U.S.-centric, with its core operations in San Diego. For international investors, the key point is that SKYE is a Nasdaq-listed U.S. biotech, not a European healthcare company, and its operating, regulatory, and capital-markets exposure is therefore primarily American. Recent company highlights include its 2024 and 2025 financial and business updates, continued development work on nimacimab, and plans to broaden the pipeline through in-licensing or acquisitions of complementary metabolic health assets. A particularly important recent development came in March 2026, when Skye disclosed that it had received a Nasdaq deficiency notice because its share price had traded below the minimum $1.00 requirement for 30 consecutive business days. The notice does not immediately affect trading, but it is a material monitoring point for equity holders.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
